Pepgen Inc (PEPG)

$5.32 -0.83 (-13.50%)
Market Cap 425.06M
Revenue (ttm) 0.00
Net Income (ttm) -89.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,340,700
Avg Vol 741,702
Day's Range N/A - N/A
Shares Out 69.12M
Stochastic %K 17%
Beta 1.87
Analysts Strong Sell
Price Target $10.86

Company Profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 797 0979
Website: pepgen.com
Address:
321 Harrison Avenue, 8th Floor, Boston, United States
ravioli
ravioli Mar. 12 at 4:02 PM
$PEPG if it’s on hold shouldn’t it be under $2 or $1 ??? What am I missing here?? I have April puts .
0 · Reply
ravioli
ravioli Mar. 12 at 3:25 PM
$PEPG got April puts here !!
0 · Reply
Quantumup
Quantumup Mar. 9 at 2:45 PM
Jefferies reiterated $DYN Buy/$50, and said that it Remains 70-80%+ Confident in an AA Approval by 1Q27. $PEPG $RNA ARWR SNY $CAPR $EWTX PTCT SRPT Here's what Jefferies had to say in its note: At MDA (Mar 8-11): (1) In DM1 ($3B+ oppty), z-basivarsen (ASO) starts a confirmatory Phase III trial designed to convert an AA accelerated approval (based on pivotal Phase II results in Q1:27) into a full approval. (2) In DMD Exon 51 ($500M+ oppty), z-rostudirsen (PMO) shares new 24-month cardiopulmonary function data from the Phase I/II OLE extension. We remain 70-80%+ confident in an AA approval by Q1:27, due to recent best-in-class pivotal Phase II data.
0 · Reply
aletz
aletz Mar. 6 at 9:20 AM
$PEPG https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/ Featured in the AI Catalyst Scanner for the second week of March. This scanner integrates advanced AI research with machine learning patterns, leveraging over a decade of data alongside catalyst-driven quality and technical indicators. Disclaimer: BSI score is a rating derived from combined AI and ML models and does not guarantee specific outcomes.
0 · Reply
GTMStox
GTMStox Mar. 5 at 5:15 PM
$PEPG POS
0 · Reply
lob11
lob11 Mar. 5 at 1:53 PM
$PEPG Why is HHS and the FDA run by such a group of quacks? It's embarrassing
0 · Reply
briefingcom
briefingcom Mar. 5 at 1:01 PM
$PEPG: PepGen (-20.5%) announces regulatory updates related to the FREEDOM2 trial; U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260304160606PEPG&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
StockConsultant
StockConsultant Mar. 5 at 1:40 AM
$PEPG PepGen stock, strong day, watch for a top of range breakout at https://stockconsultant.com/?PEPG
0 · Reply
RazorbackAJ
RazorbackAJ Mar. 4 at 10:30 PM
$PEPG Changed my mind based on the terrible price action. Shorted now with tight stop at $6.25. Follow for such precise calls with exact stop loss levels.
0 · Reply
showmethemoney75
showmethemoney75 Mar. 4 at 10:16 PM
$PEPG Going to open in the low 4s tomorrow
0 · Reply
Latest News on PEPG
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 5, 2026, 8:00 PM EST - 8 days ago

PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

US FDA puts partial clinical hold on PepGen's muscle disease drug trial

Mar 4, 2026, 4:56 PM EST - 9 days ago

US FDA puts partial clinical hold on PepGen's muscle disease drug trial

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

Mar 4, 2026, 4:05 PM EST - 9 days ago

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

PepGen Announces Regulatory Updates on FREEDOM2

Mar 4, 2026, 4:03 PM EST - 9 days ago

PepGen Announces Regulatory Updates on FREEDOM2

PepGen to Participate in the Leerink Global Healthcare Conference

Mar 3, 2026, 7:00 AM EST - 10 days ago

PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

Dec 9, 2025, 7:00 AM EST - 3 months ago

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

Dec 8, 2025, 7:00 AM EST - 3 months ago

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Nov 12, 2025, 7:05 AM EST - 4 months ago

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 7:00 AM EST - 4 months ago

PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 4 months ago

PepGen to Participate in Upcoming Investor Conferences

PepGen: DMD Discontinued, Ways To Go With DM1

Oct 7, 2025, 6:38 PM EDT - 5 months ago

PepGen: DMD Discontinued, Ways To Go With DM1

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

Oct 2, 2025, 7:00 AM EDT - 5 months ago

PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Sep 26, 2025, 4:01 PM EDT - 6 months ago

PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

Sep 25, 2025, 9:46 AM EDT - 6 months ago

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Announces Pricing of $100 Million Public Offering

Sep 24, 2025, 10:51 PM EDT - 6 months ago

PepGen Announces Pricing of $100 Million Public Offering

PepGen Announces Proposed Public Offering

Sep 24, 2025, 4:21 PM EDT - 6 months ago

PepGen Announces Proposed Public Offering

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

Sep 24, 2025, 4:16 PM EDT - 6 months ago

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 7 months ago

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 30, 2025, 5:41 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 29, 2025, 10:33 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Jul 23, 2025, 11:22 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Jun 23, 2025, 9:00 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

Jun 16, 2025, 10:39 AM EDT - 9 months ago

Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 10, 2025, 10:44 AM EDT - 9 months ago

PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

May 29, 2025, 9:19 AM EDT - 10 months ago

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen to discontinue development of experimental Duchenne therapy; shares drop

May 28, 2025, 6:21 PM EDT - 10 months ago

PepGen to discontinue development of experimental Duchenne therapy; shares drop

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

May 28, 2025, 4:05 PM EDT - 10 months ago

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 10 months ago

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

ravioli
ravioli Mar. 12 at 4:02 PM
$PEPG if it’s on hold shouldn’t it be under $2 or $1 ??? What am I missing here?? I have April puts .
0 · Reply
ravioli
ravioli Mar. 12 at 3:25 PM
$PEPG got April puts here !!
0 · Reply
Quantumup
Quantumup Mar. 9 at 2:45 PM
Jefferies reiterated $DYN Buy/$50, and said that it Remains 70-80%+ Confident in an AA Approval by 1Q27. $PEPG $RNA ARWR SNY $CAPR $EWTX PTCT SRPT Here's what Jefferies had to say in its note: At MDA (Mar 8-11): (1) In DM1 ($3B+ oppty), z-basivarsen (ASO) starts a confirmatory Phase III trial designed to convert an AA accelerated approval (based on pivotal Phase II results in Q1:27) into a full approval. (2) In DMD Exon 51 ($500M+ oppty), z-rostudirsen (PMO) shares new 24-month cardiopulmonary function data from the Phase I/II OLE extension. We remain 70-80%+ confident in an AA approval by Q1:27, due to recent best-in-class pivotal Phase II data.
0 · Reply
aletz
aletz Mar. 6 at 9:20 AM
$PEPG https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/ Featured in the AI Catalyst Scanner for the second week of March. This scanner integrates advanced AI research with machine learning patterns, leveraging over a decade of data alongside catalyst-driven quality and technical indicators. Disclaimer: BSI score is a rating derived from combined AI and ML models and does not guarantee specific outcomes.
0 · Reply
GTMStox
GTMStox Mar. 5 at 5:15 PM
$PEPG POS
0 · Reply
lob11
lob11 Mar. 5 at 1:53 PM
$PEPG Why is HHS and the FDA run by such a group of quacks? It's embarrassing
0 · Reply
briefingcom
briefingcom Mar. 5 at 1:01 PM
$PEPG: PepGen (-20.5%) announces regulatory updates related to the FREEDOM2 trial; U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260304160606PEPG&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
StockConsultant
StockConsultant Mar. 5 at 1:40 AM
$PEPG PepGen stock, strong day, watch for a top of range breakout at https://stockconsultant.com/?PEPG
0 · Reply
RazorbackAJ
RazorbackAJ Mar. 4 at 10:30 PM
$PEPG Changed my mind based on the terrible price action. Shorted now with tight stop at $6.25. Follow for such precise calls with exact stop loss levels.
0 · Reply
showmethemoney75
showmethemoney75 Mar. 4 at 10:16 PM
$PEPG Going to open in the low 4s tomorrow
0 · Reply
RazorbackAJ
RazorbackAJ Mar. 4 at 9:40 PM
$PEPG Over reaction to downside - going long from $5.20 to here with current trailing stop at $4.80. Follow for such precise calls with actual stop loss levels.
0 · Reply
notreload_ai
notreload_ai Mar. 4 at 9:23 PM
$PEPG announces FDA partial clinical hold on FREEDOM2-DM1 trial due to preclinical questions, while gaining clearance in South Korea, Australia, New Zealand. https://notreload.xyz/pepgen-faces-fda-partial-hold-on-freedom2-dm1-trial/
0 · Reply
DonCorleone77
DonCorleone77 Mar. 4 at 9:14 PM
$PEPG PepGen announce FDA placed partial clinical hold on Phase 2 trial of PGN-EDODM1 PepGen announced regulatory updates related to the Freedom2 trial. The U.S. Food and Drug Administration has placed a partial clinical hold on the Freedom2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1. The partial clinical hold questions raised by FDA relate to previously submitted preclinical pharmacology and toxicology studies. The partial clinical hold did not cite any questions regarding blinded clinical data from the Phase 1 Freedom study previously submitted to the FDA in order to initiate the Freedom2 study in the U.S. As part of its ongoing dialogue with the FDA, the Company is submitting additional analyses, including the recently unblinded Freedom data, and is committed to working with the FDA to address their questions as quickly as possible. PepGen was recently cleared to open the Freedom2 study in New Zealand, Australia, and South Korea. The Company expects to report data from the 5 mg/kg cohort of Freedom2 in the first quarter of 2026, and from the 10 mg/kg cohort in the second half of 2026.
0 · Reply
StockNews_Live
StockNews_Live Mar. 4 at 9:07 PM
$PEPG PepGen Inc. reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights. The company announced that the Phase 1 FREEDOM trial delivered compelling data…
0 · Reply
AllandaleCapital
AllandaleCapital Mar. 4 at 9:02 PM
$PEPG 👀
0 · Reply
DonCorleone77
DonCorleone77 Mar. 4 at 9:02 PM
$PEPG PepGen Inc trading halted, news pending
0 · Reply
optionsReasy
optionsReasy Feb. 28 at 7:46 PM
$PEPG https://www.marketbeat.com/instant-alerts/pepgen-nasdaqpepg-now-covered-by-analysts-at-oppenheimer-2026-02-25/
0 · Reply
optionsReasy
optionsReasy Feb. 26 at 8:44 PM
$PEPG if you are smart you’d buy more while you have the chance. Institutions are buying more daily.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 24 at 9:06 PM
$PEPG RSI: 59.20, MACD: 0.2507 Vol: 0.80, MA20: 5.66, MA50: 5.77 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 7:54 PM
$PEPG Current Stock Price: $6.32 Contracts to trade: $6.0 PEPG Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 62% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
erevnon
erevnon Feb. 18 at 3:54 PM
Guggenheim maintains PepGen $PEPG at Buy and raises the price target from $6 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
optionsReasy
optionsReasy Feb. 18 at 12:05 AM
$PEPG holding up like a G. If this holds till Friday forgetttaboutit
0 · Reply